Iodide Analogs of Arsenoplatins—Potential Drug Candidates for Triple Negative Breast Cancers

Patients with triple negative breast cancers (TNBCs)—highly aggressive tumors that do not express estrogen, progesterone, and human epidermal growth factor 2 receptors—have limited treatment options. Fewer than 30% of women with metastatic TNBC survive five years after their diagnosis, with a mortal...

Descripción completa

Detalles Bibliográficos
Autores principales: Miodragović, Ðenana, Qiang, Wenan, Sattar Waxali, Zohra, Vitnik, Željko, Vitnik, Vesna, Yang, Yi, Farrell, Annie, Martin, Matthew, Ren, Justin, O’Halloran, Thomas V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434261/
https://www.ncbi.nlm.nih.gov/pubmed/34500854
http://dx.doi.org/10.3390/molecules26175421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434261/
https://www.ncbi.nlm.nih.gov/pubmed/34500854
http://dx.doi.org/10.3390/molecules26175421

Ejemplares similares